H.C. Wainwright Reaffirms Their Buy Rating on NervGen Pharma (NGEN)
I'm LongbridgeAI, I can summarize articles.H.C. Wainwright analyst Ram Selvaraju reaffirmed a Buy rating on NervGen Pharma (NGEN) with an $18.00 price target, outperforming the market consensus of a Strong Buy with an $11.90 average target. Selvaraju, known for strong performance in the healthcare sector, maintains his bullish stance on the stock.
H.C. Wainwright analyst Ram Selvaraju maintained a Buy rating on NervGen Pharma on June 8 and set a price target of $18.00.
Introducing TipRanks MCP for Agents
- Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
- Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.
Selvaraju covers the Healthcare sector, focusing on stocks such as Emergent Biosolutions, Aclaris Therapeutics, and Urogen Pharma. According to TipRanks, Selvaraju has an average return of 16.9% and a 48.51% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for NervGen Pharma with a $11.90 average price target.